AI Article Synopsis
- The study explores how analyzing circulating tumor cells (CTCs) could enhance cancer treatment, specifically focusing on prostate cancer.
- Researchers developed a microfluidic chip using permalloy to efficiently isolate prostate cancer cells from blood using antibodies that target a specific protein (PSMA).
- Initial tests show that this device can successfully isolate prostate cancer cells with a sensitivity of up to 98% even at low concentrations of 20 cells/mL, while also maintaining a flow rate of 100 μL/min.
Article Abstract
The quantitative and qualitative analysis of circulating tumor cells (CTCs) has the potential to improve the clinical management of several cancers, including prostate cancer. As such, there is much interest in the isolation of CTCs from the peripheral blood of cancer patients. We report the design, fabrication, and proof-of-principle testing of an integrated permalloy-based microfluidic chip for immunomagnetic isolation of blood-borne prostate cancer cells using an antibody targeting prostate surface membrane antigen (PSMA). The preliminary results using spiked blood samples indicate that the proposed device is consistently capable of isolating prostate cancer cells with high sensitivity (up to 98 %) at clinically relevant low concentrations (down to 20 cells/mL) and an acceptable throughput (100 μL/min).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10544-016-0041-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!